CKD-aP: Beyond the Surface
Leonie Kraft, MD
Kappa-Opioid Settings: Real-World Evidence Insights
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
Quantifying CKD-aP: Tools for Better Care
James Burton, DM, FRCP
Is CKD-aP Hiding in Your Dialysis Center?
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Javed Butler, MD, MPH, MBA
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
FSGS 360°: From Patient Experience to Precision Medicine
Kenneth Lieberman, MD
Meghan Sise, MD
Vladimir Tesar
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Jonathan Barratt, MD, PhD
Sydney Tang, MBBS, MD
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Daniel Judge, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Kevin Alexander, MD
Difelikefalin: Managing CKD-aP for Improved Quality of Life
Jörg Latus, MD
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Ahmad Masri, MD, MS
Optimizing VNS Parameters: Keys to Therapeutic Success
Raman Sankar, MD, PhD
Scott Aaronson, MD
Modern Neuromodulation: Vagus Nerve Stimulation in Advancing Care for Patients With Drug-Resistant Epilepsy and Treatment-Resistant Depression